AMAG Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences
RBC Capital Markets Global Healthcare Conference 2013
LEXINGTON, Mass. -- February 21, 2013
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William Heiden,
AMAG’s chief executive officer, will participate in the RBC Capital Markets
Global Healthcare Conference on Tuesday, February 26, 2013 at 9:30 am ET in
New York and the Cowen and Company 33^rd Annual Healthcare Conference on
Monday, March 4, 2013 at 2:50 pm ET in Boston. The presentations will include
a company overview and business update, followed by a question and answer
session with investors.
A live webcast of the presentations will be accessible through the Investors
section of the company’s website at www.amagpharma.com. Following the
conferences, the webcasts will be archived on the AMAG Pharmaceuticals, Inc.
website until April 4, 2013.
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that
manufactures and markets Feraheme® (ferumoxytol) Injection for Intravenous
(IV) use in the United States. Along with driving organic growth of its lead
product, AMAG intends to expand its portfolio with additional commercial-stage
specialty pharmaceuticals. The company is seeking complementary products that
leverage the company’s commercial footprint and focus on hematology and
oncology centers and hospital infusion centers. For additional company
information, please visit www.amagpharma.com.
AMAG Pharmaceuticals, Inc.
Amy Sullivan, 617-498-3303
Press spacebar to pause and continue. Press esc to stop.